What Payers are Thinking

Our recent market research with payers who collectively represent 140 million covered lives revealed that 68% of payer decision makers view health outcomes and pharmacoeconomic data as "somewhat" or "very important" when making new coverage decisions. Approximately 50% of the same respondents said that pharmaceutical companies are not doing a good job of supplying them with credible HEOR data. 
 
These payers also identified the specific branded pharmaceutical and biotech products they recognize as having a solid value proposition based on strong evidence, as well as those that do not.  Find out more

How to Accelerate Commercial Success

Start early, communicate often, and coordinate closely across the organization. Whether it's your value proposition, patient assistance program (PAP), coding strategy, or weighing your product distribution options, it's never too early to consider all aspects of your product's commercialization plan and begin communicating often and coordinating closely across the organization. In order to maximize patient access, we recommend taking the following 12 steps early in your product's life cycle. Learn more

What Oncologists are Thinking

On July 9, 3 days after ASCO broadcast an electronic announcement to its membership regarding the US FDA's new indication for pemetrexed in patients with NSCLC, the market research group at Xcenda e-mailed a single research query to a large fraction of the American oncology community (ie, over 300 oncologists).

At this point, how do you expect to utilize (or not utilize) pemetrexed as a maintenance therapy in the first-line management of patients with advanced non-squamous NSCLC?  View results

Healthcare Reform Update

Late last night, the House of Representatives passed two bills, winning final approval of sweeping health care reform legislation that aims to contain healthcare costs and expand coverage to millions of uninsured Americans. The House dispensed with the anticipated "deem and pass" approach, and instead took two separate votes on the reform legislation. First, the House passed - by a vote of...... Read full article